Endometrial Cancer Trial, Recruiting NCT06432478 Sponsor: Royal North Shore Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06432478
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give their informed consent to participate in the study
  • People who have been recommended to receive a type of internal radiation treatment called intracavitary brachytherapy
  • People whose cancer has been staged between FIGO Stage I and Stage IVA (confirm with trial site if unsure of your stage)
  • People with a general health and activity level rated as ECOG 0 to 2, meaning they are able to carry out at least some daily activities
  • People diagnosed with primary endometrial cancer, primary vaginal cancer, primary vulvar cancer, or recurrent gynaecological cancer

Who may not be able to join:

  • People who are pregnant
  • People for whom brachytherapy (internal radiation) is medically unsuitable or not recommended
  • People who have inflammatory bowel disease, a history of abdominal adhesions (internal scar tissue), or a history of bowel obstruction
  • People who have had a kidney transplant or have a horseshoe kidney (a specific kidney shape present from birth)
  • People whose cancer involves significant spread into blood or lymph vessels (LVSI) or has grown into the side walls of the pelvis
  • People whose treatment would require a more complex type of brachytherapy that involves needles placed directly into tissue (called interstitial brachytherapy)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marita Morgia, MD, Royal North Shore Hospital

Phone: 9463 1300

Australian sites

Royal North Shore Hospital, St Leonards, New South Wales
02 9463 1339

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Royal North Shore Hospital
Registry
ClinicalTrials.gov
Start date
24 November 2023
Est. completion
1 September 2028

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Successful treatment of gynaecological HDR brachytherapy patients with 3D printed intracavitary applicators.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov